Anders Tuv

Anders Tuv has extensive experience in the pharmaceutical and biotech industries. Anders began their career in 2011 as the President & Chief Investment Officer at RADFORSK Investeringsstiftelse, where they were responsible for creating and investing in life sciences companies. Anders held this position until the present.

In 2012, Tuv joined Nykode Therapeutics as a Non-executive Director and later became the Chairman of the Board. Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the development of vaccines and immunotherapies for cancer and infectious diseases. Tuv served in these roles until 2021.

Anders also worked as an Advisor at Aeternum Management AS starting from 2021. Aeternum is an active owner of high-quality companies in the Nordics.

In 2021, Tuv joined OnDosis as a Non-executive Director. OnDosis is a company that develops technology for flexible and individualized dosing of oral medicines.

From 2016 to 2018, Tuv served as a Non-executive Director and later as Chairman of the Board at Zelluna Immunotherapy. Anders also briefly held the CEO position at Zelluna Immunotherapy from 2016 to 2017.

Tuv has held positions as a Non-executive Director and acting CFO at ArtBio since 2019.

Anders served as a Non-executive Director at Nextera AS from 2012 to the present. Nextera is a company focused on cancer and autoimmunity research.

Tuv has also served as an Advisor at Antler, a global early-stage venture capital firm, since 2018.

Anders is also an Advisor at Norwegian Mycelium (NoMy) since 2020.

Lastly, Tuv has been a member of the Nomination Committee at Targovax ASA since 2015. Targovax is developing immunotherapy platforms for patients with cancer.

Anders Tuv attended INSEAD in 2015 and completed the Executive Board Program. Anders also obtained a certification in Pharma-Biotech Product & Company Valuation, although the institution and the specific month and year of completion are not provided.